Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis
- PMID: 22967776
- DOI: 10.4088/JCP.12r07694
Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis
Abstract
Objective: To carry out a systematic review of the risk factors for, and incidence of, major depressive episode (MDE) related to antiviral therapy for chronic hepatitis C.
Data sources: The MEDLINE, PsycINFO, and Cochrane databases were searched to locate articles published from the earliest available online year until June 2011 using the keywords hepatitis C, interferon-alpha, peginterferon, pegylated interferon, depression, and mood and Boolean operators. Articles written in English, Spanish, and French were included.
Study selection: Prospective studies reporting incidence of interferon-alpha-induced MDE were included. At baseline, patients did not present a DSM-IV/ICD depressive episode, and evaluation was performed by a trained clinician. Twenty-six observational studies met the inclusion criteria.
Data extraction: Extracted data included authors, year of publication, design, characteristics of the population, viral coinfection, adjunctive psychopharmacology, instruments to assess depression, dose and type of interferon-alpha, adjunctive ribavirin treatment, and follow-up time. Outcome of incidence of MDE (primary outcome measure) was abstracted, as were potential predictive variables.
Data synthesis: A full review was performed. Meta-analysis of the cumulative incidence of induced MDE as a function of time was carried out. Odds ratios (ORs) and mean differences were used to estimate the strength of association of variables.
Results: Overall cumulative incidence of depression was 0.25 (95% CI, 0.16 to 0.35) and 0.28 (95% CI, 0.17 to 0.42) at 24 and 48 weeks of treatment, respectively. According to our analysis, high baseline levels of interleukin 6 (mean difference = 1.81; 95% CI, 1.09 to 2.52), female gender (OR = 1.40; 95% CI, 1.02 to 1.91), history of MDE (OR = 3.96; 95% CI, 2.52 to 6.21), history of psychiatric disorder (OR = 3.18; 95% CI, 1.60 to 6.32), subthreshold depressive symptoms (mean difference = 0.96; 95% CI, 0.31 to 1.61), and low educational level (mean difference = -0.99; 95% CI, -1.59 to -0.39) were predictive variables of MDE during antiviral treatment.
Conclusions: One in 4 chronic hepatitis C patients who start interferon and ribavirin treatment will develop an induced major depressive episode. Clinicians should attempt a full evaluation of patients before starting antiviral treatment in order to identify those at risk of developing interferon-induced depression.
© Copyright 2012 Physicians Postgraduate Press, Inc.
Similar articles
-
Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: A critical systematic review.J Affect Disord. 2017 Feb;209:235-245. doi: 10.1016/j.jad.2016.11.039. Epub 2016 Nov 27. J Affect Disord. 2017. PMID: 27936453 Review.
-
DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.Arq Gastroenterol. 2016 Jan-Mar;53(1):20-4. doi: 10.1590/S0004-28032016000100005. Arq Gastroenterol. 2016. PMID: 27281500
-
Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis.J Clin Psychiatry. 2014 Oct;75(10):e1113-21. doi: 10.4088/JCP.13r08800. J Clin Psychiatry. 2014. PMID: 25373120 Review.
-
Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.J Psychosom Res. 2014 Aug;77(2):109-15. doi: 10.1016/j.jpsychores.2014.05.008. Epub 2014 Jun 2. J Psychosom Res. 2014. PMID: 25077851
-
Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals.World J Biol Psychiatry. 2010 Oct;11(7):914-8. doi: 10.3109/15622975.2010.504282. World J Biol Psychiatry. 2010. PMID: 20642400
Cited by
-
Th17 Cells, Glucocorticoid Resistance, and Depression.Cells. 2023 Nov 30;12(23):2749. doi: 10.3390/cells12232749. Cells. 2023. PMID: 38067176 Free PMC article. Review.
-
Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management.World Psychiatry. 2023 Oct;22(3):366-387. doi: 10.1002/wps.21110. World Psychiatry. 2023. PMID: 37713568 Free PMC article.
-
Combining inflammatory miRNA molecules as diagnostic biomarkers for depression: a clinical study.Front Psychiatry. 2023 Jul 27;14:1227618. doi: 10.3389/fpsyt.2023.1227618. eCollection 2023. Front Psychiatry. 2023. PMID: 37575572 Free PMC article.
-
Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study.Front Pharmacol. 2023 Jul 19;14:1191843. doi: 10.3389/fphar.2023.1191843. eCollection 2023. Front Pharmacol. 2023. PMID: 37538181 Free PMC article.
-
A Review of the Impact of Maternal Prenatal Stress on Offspring Microbiota and Metabolites.Metabolites. 2023 Apr 9;13(4):535. doi: 10.3390/metabo13040535. Metabolites. 2023. PMID: 37110193 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous